^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PDGFRA D842V

    i
    Entrez ID:
    5156
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) (NCT05609942)
    Phase 1
    Blueprint Medicines Corporation
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    09/25/2023
    Primary completion :
    01/14/2025
    Completion :
    12/31/2025
    PDGFRA
    |
    KIT mutation • PDGFRA D842V • PDGFRA mutation
    |
    azacitidine • elenestinib (BLU-263)
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (NCT05554341)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/10/2024
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    PDGFRA
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    Imatinib TDM in GIST (NCT05493215)
    Phase 2
    Reema A. Patel
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    03/26/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    KIT • PDGFRA
    |
    KIT mutation • PDGFRA D842V • PDGFRA mutation
    |
    imatinib
    French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients (AVIATOR2020) (NCT04927260)
    Phase N/A
    Centre Leon Berard
    Active, not recruiting
    Last update posted :
    12/25/2023
    Initiation :
    03/31/2021
    Primary completion :
    04/30/2024
    Completion :
    12/31/2024
    PDGFRA
    |
    PDGFRA D842V
    |
    Ayvakit (avapritinib)
    (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors (NCT02508532)
    Phase 1
    Blueprint Medicines Corporation
    Completed
    Last update posted :
    06/21/2022
    Initiation :
    08/01/2015
    Primary completion :
    03/06/2020
    Completion :
    06/03/2021
    KIT • PDGFRA
    |
    PDGFRA D842V • PDGFRA mutation
    |
    Ayvakit (avapritinib)
    Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST (NCT02847429)
    Phase 3
    Arog Pharmaceuticals, Inc.
    Active, not recruiting
    Last update posted :
    01/22/2021
    Initiation :
    08/01/2016
    Primary completion :
    08/01/2021
    Completion :
    08/01/2021
    PDGFRA
    |
    PDGFRA D842V • PDGFRA mutation
    |
    crenolanib (ARO-002)
    Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST (NCT03862885)
    Phase N/A
    Blueprint Medicines Corporation
    Approved for marketing
    Last update posted :
    07/27/2020
    PDGFRA
    |
    PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation
    |
    Ayvakit (avapritinib)
    A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors (NCT02642016)
    Phase 1
    Celldex Therapeutics
    Completed
    Last update posted :
    06/12/2019
    Initiation :
    12/01/2015
    Primary completion :
    01/30/2018
    Completion :
    06/04/2019
    KIT • PDGFRA
    |
    KIT positive • PDGFRA D842V • KIT expression
    |
    CDX-0158
    Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene (NCT01243346)
    Phase 2
    Arog Pharmaceuticals, Inc.
    Completed
    Last update posted :
    06/28/2018
    Initiation :
    04/01/2011
    Primary completion :
    07/01/2014
    Completion :
    07/01/2014
    PDGFRA
    |
    PDGFRA D842V • PDGFRA mutation
    |
    crenolanib (ARO-002)